Endoscopic Ultrasound for the Diagnosis of Disease and Staging of Cancers in Adult Patients with Gastroenterological Or Oncological Disease: Guidelines
Total Page:16
File Type:pdf, Size:1020Kb
TITLE: Endoscopic Ultrasound for the Diagnosis of Disease and Staging of Cancers in Adult Patients with Gastroenterological or Oncological Disease: Guidelines DATE: 26 February 2014 RESEARCH QUESTION What are the evidence-based guidelines for the use of endoscopic ultrasound in the diagnosis of disease and staging of cancers in adult patient with gastroenterological or oncological disease? KEY MESSAGE Thirteen evidence-based guidelines regarding the use of endoscopic ultrasound in the diagnosis of disease and staging of cancers in adult patient with gastroenterological or oncological disease were identified. METHODS A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 2), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to guidelines. The search was also limited to English language documents published between January 1, 2009 and February 11, 2014. Internet links were provided, where available. The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article. RESULTS Thirteen evidence-based guidelines regarding the staging and diagnosis of cancer and of gastrointestinal diseases were identified. Additional references of potential interest are provided in the appendix. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. OVERALL SUMMARY OF FINDINGS Thirteen evidence-based guidelines regarding the use of endoscopic ultrasound (EUS) for the diagnosis and staging of various cancers and gastrointestinal diseases were identified. A summary of the recommendations is presented in Table 1 and further detail regarding the recommendations is available in the full text of the guidelines. Table 1: Summary of the Recommendations Regarding the use of EUS for the diagnosis and Staging of Cancer and Gastrointestinal Diseases Indication Recommendation Rectal and Colorectal • EUS is recommended for the staging of rectal cancer.1,12 Cancer • EUS is recommended for the preoperative locoregional staging of colorectal cancer.3 • Endorectal U/S is particularly useful for staging in patients for whom MRI is contraindicated or if disease is amenable to local excision.10 • Endoluminal U/S can play a complimentary role in the assessment of tumour depth in early stages of disease.11 Lung Cancer • EUS with FNA is less invasive than surgical staging and has a lower risk of complications.2 Endobrachial U/S-FNA with or without EUS-FNA should be offered to patients with suspected lung cancer prior to mediastinoscopy.2 • Radial endobrachial U/S shows potential for a high diagnostic yield in patients with suspected lung cancer.6 • EUS may be helpful for the diagnosis and staging of NSCLC.12 • EUS-FNA has 91% sensitivity and can be an option for staging NSCLC at mediastinum and all abnormal scans should be followed up by tissue biopsy.5 Esophageal Cancer • EUS-FNA in conjunction with cross-sectional imaging is recommended for accurate staging of esophageal carcinoma.4 • CT is recommended for initial staging of esophageal and gastric cancers, however, additional staging may be done with EUS8 and may be helpful for staging of esophageal cancers.12 • EUS-FNA should be performed when the cytological result is likely to affect the decision regarding treatment option.13 • EUS is not helpful for the detailed staging of mucosal disease.8 Gastroenteropancreatic • Multi-modal imaging (using CT, MRI, SSRS, or PET/CT with neuroendocrine Ga68) is recommended for primary imaging, and additional (including carcinoid) imaging can be done with EUS.7 tumours Medistinal adenopathy • Radial EUS within the esophagus provides similar information and Mediastinal lesions to that of axial CT for the imaging of medistinal adenopathy.9 unrelated to lung or • Transesophageal EUS-FNA is recommended for the initial esophageal evaluation of solid mediastinal lesions and enlarged lymph cancer nodes of unknown origin.13 Pancreatic cancer • EUS is likely helpful for differential diagnosis of pancreatic cyst.12 • EUS-FNA is recommended as a first line procedure in Endoscopic U/S for the Diagnosis and Staging of GI or Oncological Disease 2 Table 1: Summary of the Recommendations Regarding the use of EUS for the diagnosis and Staging of Cancer and Gastrointestinal Diseases Indication Recommendation suspected pancreatic cancer.13 Other Cancers • EUS is likely helpful for: 12 o differential diagnosis of subepithelial lesions o assessment of peritoneal involvement in patients with gastric cancer.12 • EUS is likely helpful for the assessment of mucosa-associated lymphoid tissue lymphoma,12 and EUS-FNA of lymph nodes of unknown origin is recommended if they are accessible and the results are likely to change treatment.13 • EUS may be helpful for staging of submucosal GI tumours.13 • EUS-FNA of suspected distant metastases detected during EUS examination is recommended when there is the potential to change patient management.13 • EUS-FNA of adrenal gland masses, suspected distant metastases, and focal solid liver lesions is recommended when malignancy would change patient management.13 Choledocholithiasis • Preoperative EUS is recommended for patients with intermediate probability of choledocholithiasis.14 Gastric wall thickness • EUS may be helpful for the imaging of thickened gastric folds.12 • EUS-TCB, especially when combined with EUS-FNA, is likely accurate for investigation of diffuse esophageal/gastric wall thickening. Pancreatitis • EUS is likely helpful for the diagnosis of chronic pancreatitis and differential diagnosis of a solid mass in patients with chronic pancreatitis.12 Other GI Indications • EUS likely helpful in the diagnosis of common bile duct and gallbladder stones.12 CT = computed tomography; EUS = endoscopic ultrasound; FNA = fine-needle aspiration; GA68 = gallium-68; GI = gastrointestinal; MRI = magnetic resonance imaging; NSCLC = non-small cell lung cancer; PET = positron emission tomography; SSRS = somatostatin receptor scintigraphy; TCB = trucut biopsy; U/S = ultrasound Endoscopic U/S for the Diagnosis and Staging of GI or Oncological Disease 3 REFERENCES SUMMARIZED Guidelines and Recommendations Cancer 1. National Comprehensive Cancer Network. Rectal cancer. Version 3.2014. Fort Washington (PA): The Network; 2014. Free subscription required. See: Clinical Evaluation/Staging. p. MS-8 2. Scottish Intercollegiate Guidelines Network. Management of lung cancer: a national clinical guideline [Internet]. Edinburgh (GB): The Network; 2014. (SIGN publication no. 137). [cited 2014 Feb 21]. Available from: http://www.sign.ac.uk/pdf/SIGN137.pdf See: Section 5.3.6 Endoscopic sampling of the mediastinal nodes 3. ASGE Standards of Practice Committee, Fisher DA, Shergill AK, Early DS, Acosta RD, Chandrasekhara V, et al. Role of endoscopy in the staging and management of colorectal cancer. Gastrointest Endosc. 2013 Jul;78(1):8-12. PubMed: PM23664162 NGC summary: http://www.guideline.gov/content.aspx?id=46944&search=endosonography 4. ASGE Standards of Practice Committee, Evans JA, Early DS, Chandraskhara V, Chathadi KV, Fanelli RD, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2013 Mar;77(3):328-34. PubMed: PM23410694 NGC summary: http://www.guideline.gov/content.aspx?id=44119&search=endoscopic+ultrasound+and+% 22endoscopic+ultrasound%22 5. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: